The Indian government has amended the Medical Devices Rules, 2017, introducing key changes that relax requirements for outsourced sterilisation services and standardise testing fees for medical device manufacturers. The modifications aim to facilitate faster market access for eligible medical devices while aligning India’s regulatory framework with international standards. The amendments also designate the European Union as a jurisdiction with stringent regulatory requirements, joining existing listings for the United States, Japan, Canada and Australia.
What Happened
The Medical Devices (Amendment) Rules, 2026 were notified by the Ministry of Health and Family Welfare, bringing specific changes to the 2017 regulations governing medical device manufacturing and approval. The key provisions include:
– Relaxation of sterilisation requirements for devices that are supplied by third-party providers
– Standardisation of testing fees across different categories of medical devices
– Addition of the European Union to the list of jurisdictions recognised for having stringent regulatory standards
The amendment rules specify that medical devices requiring sterilisation may now rely on third-party sterilisation services without mandating in-house sterilisation facilities, subject to certain conditions and documentation requirements. The standardised fee structure replaces the previous variable fee system, with rates now fixed based on device classification.
Why It Matters
The regulatory changes represent a significant shift in India’s approach to medical device oversight, with implications for manufacturers, healthcare providers and patients. By permitting outsourced sterilisation, the rules address a key operational constraint that many small and medium-sized manufacturers have faced when establishing production facilities. The move could reduce capital expenditure requirements for companies seeking to enter the Indian market.
Adding the EU to the list of stringent regulatory jurisdictions signals India’s intent to harmonise its approval processes with those of major global markets. This alignment may streamline the pathway for European medical technology companies to export products to India while ensuring that imported devices meet comparable safety standards.
However, the ultimate impact on device availability and patient safety will depend on the effectiveness of implementation and oversight by the Central Drugs Standard Control Organisation (CDSCO).
Background and Context
India’s medical device regulatory framework has undergone substantial evolution since the Medical Devices Rules, 2017 replaced earlier guidelines. The 2017 rules introduced a risk-based classification system for medical devices, ranging from Class A (low risk) to Class D (high risk), with corresponding regulatory requirements.
The decision to relax sterilisation requirements comes amid growing pressure to reduce barriers for medical device manufacturers while maintaining safety standards. Many manufacturers, particularly smaller enterprises, have cited the requirement for dedicated sterilisation facilities as a significant cost barrier to market entry.
The inclusion of the EU as a stringent regulatory jurisdiction reflects India’s broader strategy to align with international regulatory norms. The EU’s Medical Device Regulation (MDR) 2017/745, which came into full application in 2021, represents one of the world’s most comprehensive regulatory frameworks for medical devices. By recognising EU standards, India positions itself to accept conformity assessments from EUNotified Bodies for certain device categories.
The standardisation of testing fees addresses previous criticisms of the variable fee structure, which some manufacturers argued created unpredictability in approval costs. The new fee schedule applies uniformly across device categories, with specific rates set for different testing and approval processes.
What to Watch Next
Implementation of the amended rules will be critical to their success. The CDSCO will need to issue detailed guidelines on the documentation required for third-party sterilisation arrangements and establish quality assurance protocols for outsourced services.
Industry stakeholders are likely to monitor whether the standardised fee structure delivers the anticipated cost savings and whether the process for EU-based device approvals becomes more efficient. The changes may attract increased investment in India’s medical device manufacturing sector, particularly from companies focused on exports to global markets.
Regulatory oversight mechanisms will be essential to ensure that the relaxed sterilisation requirements do not compromise patient safety. The CDSCO may need to strengthen its inspection and monitoring capabilities to oversee third-party sterilisation providers effectively.
The amendments also raise questions about how India will handle devices from EU manufacturers that may not fully comply with Indian-specific requirements, even as EU conformity assessments are recognised. Discrepancies between regulatory approaches could create challenges in post-market surveillance and adverse event reporting.
Conclusion
The amendment to India’s Medical Devices Rules represents a calculated balancing act between facilitating market access and maintaining regulatory standards. By easing sterilisation requirements and standardising fees, the government has addressed key operational constraints faced by manufacturers while signalling alignment with international regulatory frameworks through EU recognition.
The success of these changes will ultimately depend on the quality of implementation and the robustness of oversight mechanisms. If executed effectively, the amendments could accelerate the availability of medical devices in India while supporting the growth of a more competitive domestic manufacturing sector. However, careful attention will be required to ensure that the relaxation of certain requirements does not inadvertently compromise patient safety or create new regulatory complexities.
Sources: The Hindu – National (https://www.thehindu.com/news/national/medical-device-rules-eased-for-outsourced-sterilisation-eu-added-to-stringent-regulatory-jurisdictions/article71384282.ece)
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: The Hindu – National — source
